Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — A hand-held internally illuminated ETDRS device provided accurate and repeatable visual acuity ...

The early treatment diabetic retinopathy study (ETDRS) 1 showed that macular grid and focal laser therapy reduces the risk of moderate visual loss in diabetic eyes with clinically significant macular ...

Please provide your email address to receive an email when new articles are posted on . Dyop and ETDRS results were comparable under photopic conditions. However, Dyop results were worse under mesopic ...

To determine the average time-point at which it is best to define ‘sub-optimal response’ after ranibizumab treatment for diabetic macular edema (DME) based on the data obtained from real-life clinical ...

Patients with diabetic macular edema in higher dose cohorts showed a mean BCVA gain of approximately 10 ETDRS letters sustained through 24 weeks after a single intravitreal injection Patients with wet ...

In all subjects (n=14), the mean change from baseline of visual acuity in TE showed an improvement of +29 ETDRS letters (-0.58 LogMAR) that was both clinically and statistically significant (p = ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative ...

September 25, 2012 — Patients with central retinal vein occlusion (CRVO) who received aflibercept achieved significant improvement in visual acuity, compared with those receiving sham treatment in 2 ...

A smartphone-based test for visual acuity is as accurate and repeatable as currently available standard visual acuity tests, according to a new study published online May 28 in JAMA Ophthalmology. The ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key ...

Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion site Evidence of retinal structural improvement persisted out to 3 ...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...